REDWOOD CITY, Calif., Jan. 27, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Paul J. Hastings, OncoMed’s Chairman and Chief Executive Officer, will speak at two upcoming investor conferences in February.
Help employers find you! Check out all the jobs and post your resume.
